Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer

Published:2015-08-29 Issue:1 Volume:13 Page:
ISSN:1479-5876
Container-title:Journal of Translational Medicine
language:en
Short-container-title:J Transl Med

Author:

Madoz-Gúrpide Juan,Zazo Sandra,Chamizo Cristina,Casado Victoria,Caramés Cristina,Gavín Eduardo,Cristóbal Ion,García-Foncillas Jesús,Rojo Federico

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12967-015-0633-7

Reference50 articles.

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11–30. doi: 10.3322/caac.21166

2. Licciardello JT, Spitz MR, Hong WK (1989) Multiple primary cancer in patients with cancer of the head and neck: second cancer of the head and neck, esophagus, and lung. Int J Radiat Oncol Biol Phys 17:467–476

3. Gold KA, Lee HY, Kim ES (2009) Targeted therapies in squamous cell carcinoma of the head and neck. Cancer 115:922–935

4. Vermorken JB, Specenier P (2010) Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol 21(Suppl 7):vii252–vii261

5. Kundu SK, Nestor M (2012) Targeted therapy in head and neck cancer. Tumour Biol 33:707–721

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Landscape of Antibody-Drug Conjugate Development in Head and Neck Cancer;JCO Precision Oncology;2024-08

2. A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer;Oral Oncology;2024-07

3. Nuclear miR-451a activates KDM7A and leads to cetuximab resistance in head and neck squamous cell carcinoma;Cellular and Molecular Life Sciences;2024-06-28

4. Crosstalk between CAFs and tumour cells in head and neck cancer;Cell Death Discovery;2024-06-26

5. c-MET pathway in human malignancies and its targeting by natural compounds for cancer therapy;Phytomedicine;2024-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3